Gritstone is a biotechnology company based in Emeryville, CA, with a vision to develop groundbreaking immunotherapies for cancers and infectious diseases. They focus on generating a therapeutic immune response by unleashing the natural power of a patient's immune system to recognize and destroy tumors or virally infected cells. Gritstone has developed two platforms, EDGE and unique delivery systems, to accurately identify T cell targets and stimulate the immune system to generate T cells and neutralizing antibodies against these targets.
Through their platforms, Gritstone has developed a portfolio of immunotherapies designed to effectively instruct the immune system to recognize and attack tumor cells and infectious agents. They are developing personalized cancer vaccines, GRANITE, to target neoantigens specific to each individual patient, as well as off-the-shelf neoantigen therapies, SLATE, targeting shared neoantigens. Additionally, Gritstone is working on next-generation vaccines for infectious diseases, including a vaccine-based immunotherapy for HIV in collaboration with Gilead Sciences, and vaccines against SARS-CoV-2 and other viral diseases.
Generated from the website